· 2h · on MSN
Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug
· 2h · on MSN
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
· 1h · on MSN
Ozempic parent’s new weight-loss drug works better, but not quite good enough
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback